Current portfolio

Hutchmed

Among the first global-focused novel drug discovery companies in China

HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

  • Sector
    Healthcare
  • Country
    Greater China
  • Fund
    The Baring Asia Private Equity Fund VII
  • Entry
    2021
  • Web
Logo

Subscribe for the latest updates

Subscribe to EQT's press releases, regulatory press releases and updates.

Type of news
Preferred language
EQT logo© EQT AB 2022. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180